Takeda Pay-for-Delay Shock; $2.5B Verdict Wipes Profit Into Loss

A U.S. federal jury in Boston has ruled against Takeda in a pay-for-delay antitrust case involving its constipation drug Amitiza, forcing the company to book a $2.5 billion legal provision and swing to a FY2025 net loss. The decision marks